NEWS
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics and TuHURA Biosciences have announced significant corporate and clinical advances.
In April 2024, both companies entered a merger agreement where TuHURA will become a wholly-owned subsidiary of Kintara, expected to close in Q3 2024. Kintara's existing stockholders will own roughly 5.5% of the combined company's stock, including a contingent value right linked to the REM-001 study milestones.
TuHURA is set to advance a Phase 3 trial for its IFx-2.0 personalized cancer vaccine in the second half of 2024.
TuHURA's ADCs offer potential partnering opportunities. A $31 million financing will support the merger, extending financial runway into late 2025.
Kintara also received a 180-day Nasdaq compliance extension to December 9, 2024.
On the clinical front, Kintara has advanced its REM-001 study for cutaneous metastatic breast cancer, having dosed four patients as of June 26, 2024. The study is supported by a $2 million NIH grant.
Near-term milestones include closing the merger in Q3 2024 and commencing TuHURA's Phase 3 trial in 2H 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
963Followers
63Following
6486Visitors
Follow
lucky Triders 369 : good news?
Jaguar8OP lucky Triders 369: Yes